Royalty Pharma plc (NASDAQ:RPRX) Shares Sold by Fmr LLC

FMR LLC lessened its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 5.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 26,379,333 shares of the biopharmaceutical company's stock after selling 1,510,810 shares during the quarter. FMR LLC owned approximately 4.48% of Royalty Pharma worth $672,937,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Verition Fund Management LLC grew its holdings in Royalty Pharma by 39.7% in the 3rd quarter. Verition Fund Management LLC now owns 27,869 shares of the biopharmaceutical company's stock valued at $788,000 after buying an additional 7,919 shares in the last quarter. Quantinno Capital Management LP lifted its stake in Royalty Pharma by 43.0% during the third quarter. Quantinno Capital Management LP now owns 56,435 shares of the biopharmaceutical company's stock worth $1,597,000 after purchasing an additional 16,982 shares in the last quarter. State Street Corp boosted its position in shares of Royalty Pharma by 0.3% during the third quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company's stock worth $269,215,000 after buying an additional 29,451 shares during the period. Barclays PLC grew its stake in shares of Royalty Pharma by 16.3% in the third quarter. Barclays PLC now owns 308,887 shares of the biopharmaceutical company's stock valued at $8,737,000 after buying an additional 43,339 shares in the last quarter. Finally, M&T Bank Corp lifted its stake in Royalty Pharma by 4.3% during the 3rd quarter. M&T Bank Corp now owns 18,749 shares of the biopharmaceutical company's stock worth $531,000 after acquiring an additional 779 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Up 0.1 %

Shares of RPRX traded up $0.04 during mid-day trading on Monday, reaching $31.99. The company's stock had a trading volume of 600,874 shares, compared to its average volume of 3,232,523. The company's 50 day moving average is $32.50 and its 200 day moving average is $29.15. The stock has a market cap of $18.44 billion, a PE ratio of 22.06, a price-to-earnings-growth ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. Equities analysts anticipate that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. TD Cowen raised Royalty Pharma to a "strong-buy" rating in a research report on Tuesday, December 24th. Citigroup reissued a "buy" rating on shares of Royalty Pharma in a research report on Friday, March 28th. One research analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $42.50.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.